Autoimmune & immunology · Phase II

Top sponsors

• Takeda 26 programs
• Teva Pharma 13 programs
• Lakefront Biotherapeutics NV 12 programs
• Anaxis Pharma 11 programs
• Chinese Academy of 11 programs
• Novartis India 11 programs
• Sanofi-Aventis U.S 10 programs
• Pacira Ireland 9 programs
• United Therapeutics Europe 8 programs
• RIGEL PHARMACEUTICALS 6 programs
• Regeneron UK 6 programs
• Vertex Pharmaceuticals (Australia) 6 programs

1. Andecaliximab

   Gilead Sciences Ireland UC

   Crohn's Disease

   phase 2 · small molecule · terminated

   1 trial →

2. Aritinercept

   Aurinia Pharmaceuticals

   Myasthenia Gravis, Generalized

   phase 2 · small molecule · active

   1 trial →

3. Atacicept 75 mg

   Serono Europe Limited

   Lupus Erythematosus, Systemic

   phase 2 · small molecule · terminated

   1 trial →

4. Atacicept Autoinjector Combination, Atacicept

   Vera Therapeutics

   Multiple Autoimmune Glomerular Diseases

   phase 2 · small molecule · active

   1 trial →

5. Autologous mesenchymal stem cells from adipose tissue.

   Lxo Ireland Designated Activity Company

   Autoimmune Diseases

   phase 2 · other · completed

   1 trial →

6. BGB-45035

   BEONE MEDICINES AUS PTY LTD

   Rheumatoid Arthritis

   phase 2 · small molecule · active

   1 trial →

7. BMS-945429 Placebo

   CSL Behring GmbH

   Rheumatoid Arthritis

   phase 2 · small molecule · completed

   1 trial →

8. BMS-986165

   Bristol-Myers Squibb

   Systemic Lupus Erythematosus

   phase 2 · small molecule · completed

   1 trial →

9. BMS-986165

   Bristol-Myers Squibb

   Lupus Nephritis

   phase 2 · small molecule · terminated

   1 trial →

10. BMS-986165

    Bristol-Myers Squibb

    Granulomatous Colitis

    phase 2 · small molecule · terminated

    1 trial →

11. Balinatunfib, Not the same excipients as test

    Sanofi-aventis Healthcare Pty Ltd

    Crohn's disease, Colitis Ulcerative

    phase 2 · small molecule · active

    1 trial →

12. Bexarotene 1% gel

    LIGAND PHARMACEUTICALS INC

    Parapsoriasis

    phase 2 · small molecule · terminated

    1 trial →

13. Bexarotene/NBUVB vs placebo NBUVB

    LIGAND PHARMACEUTICALS INC

    Psoriasis

    phase 2 · small molecule · completed

    1 trial →

14. Blinded study medication

    BRIGHT MINDS BIOSCIENCES INC.

    Knee Osteoarthritis

    phase 2 · small molecule · completed

    1 trial →

15. Bryhali

    Bausch & Lomb Incorporated

    Plaque Psoriasis

    phase 2 · small molecule · active

    1 trial →

16. C5041018

    Pfizer Australia Pty Ltd

    Ulcerative Colitis

    phase 2 · small molecule · active

    1 trial →

17. CA061-1011

    Celgene Europe Limited

    Lupus Nephritis, Systemic Lupus Erythematosus

    phase 2 · small molecule · active

    1 trial →

18. CB-01-35/01

    Cosmo Technologies Ltd

    patients with mild to moderate left-sided ulcerative colitis

    phase 2 · small molecule · active

    1 trial →

19. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Autoimmune Diseases

    phase 2 · mab · active

    1 trial →

20. CDFV890B12201

    Novartis Pharmaceuticals

    Knee Osteoarthritis

    phase 2 · small molecule · active

    1 trial →

21. CEP-701 20mg

    Teva Pharma GmbH

    Psoriasis

    phase 2 · small molecule · completed

    1 trial →

22. CF101

    Can-Fite BioPharma

    Rheumatoid Arthritis

    phase 2 · small molecule · completed

    3 trials →

23. CF101

    Can-Fite BioPharma

    Osteoarthritis of the Knee

    phase 2 · small molecule · terminated

    1 trial →

24. CF101 1mg

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 2 · small molecule · completed

    1 trial →

25. CLNP023K12201

    Novartis Pharmaceuticals

    Lupus Nephritis Class III-IV, +/- V

    phase 2 · small molecule · active

    1 trial →

26. CM336 Injection

    The First People's Hospital of Lianyungang

    Autoimmune Bullous Disease

    phase 2 · mab · active

    1 trial →

27. CMAS825D12201

    Novartis Pharmaceuticals

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 · small molecule · active

    1 trial →

28. CQUC398A12201

    Novartis Pharmaceuticals

    Knee osteoarthritis

    phase 2 · small molecule · active

    1 trial →

29. CS008

    Lacuna Pharma Pty Ltd

    Rheumatoid Arthritis

    phase 2 · small molecule · active

    1 trial →

30. CTX112

    S.A.

    Warm Autoimmune Hemolytic Anemia (WAIHA)

    phase 2 · mab · active

    1 trial →

31. CVAY736A2202

    Novartis Pharmaceuticals

    Rheumatoid Arthritis, Sjögren’s Disease, Systemic Lupus erythematosus

    phase 2 · small molecule · active

    1 trial →

32. CVAY736Q12202B

    Novartis Pharmaceuticals

    Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)

    phase 2 · small molecule · active

    1 trial →

33. CYTB323G12101

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus., Lupus Nephritis

    phase 2 · small molecule · active

    1 trial →

34. CYTB323J12201

    Novartis Pharmaceuticals

    Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)

    phase 2 · small molecule · active

    1 trial →

35. CYTB323M12101B

    Novartis Pharmaceuticals

    Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement

    phase 2 · small molecule · active

    1 trial →

36. CYTB323O12101

    Novartis Pharmaceuticals

    Treatment-resistant generalized Myasthenia Gravis

    phase 2 · small molecule · active

    1 trial →

37. Ciprofloxacin

    United Therapeutics Europe Ltd

    Crohn's Disease

    phase 2 · small molecule · completed

    1 trial →

38. Cizutamig

    Lacuna Pharma Pty Ltd

    Severe, treatment refractory primary Sjögren’s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)

    phase 2 · small molecule · active

    1 trial →

39. D9690C00006

    AstraZeneca AB

    Crohn’s Disease and an Ileostomy

    phase 2 · small molecule · active

    1 trial →

40. DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Myasthenia Gravis, Generalized

    phase 2 · small molecule · active

    1 trial →

41. DNTH103-MG-201

    Dianthus Therapeutics, Inc. /DE/

    Generalized Myasthenia Gravis

    phase 2 · small molecule · active

    1 trial →

42. DRI17821

    Sanofi-aventis Healthcare Pty Ltd

    Rheumatoid arthritis

    phase 2 · small molecule · active

    1 trial →

43. DRI17849

    Sanofi-aventis Healthcare Pty Ltd

    Psoriasis

    phase 2 · small molecule · active

    1 trial →

44. DRI18450

    Sanofi-aventis Healthcare Pty Ltd

    Crohn’s disease

    phase 2 · small molecule · active

    1 trial →

45. Dapagliflozin 10mg Tab

    The University of Hong Kong

    Lupus Nephritis

    phase 2 · small molecule · active

    1 trial →

46. Daxdilimab

    Amgen

    Lupus Nephritis

    phase 2 · small molecule · terminated

    1 trial →

47. Delayed Release 6 mercaptopurine

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 · small molecule · terminated

    1 trial →

48. Delayed Release 6MP or Calcitriol vs. Purinethol

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 · small molecule · completed

    1 trial →

Frequently asked questions